Skip to content

Clearside Biomedical, Inc.

CLSDQ

CIK 0001539029

← back to feed
Revenue (TTM)
$4.06M
−79.8% YoY Q3 Nov 2025
Net Income (TTM)
−$26.38M
−5.7% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$2.85
+11.3% YoY Q3 Nov 2025
Gross Margin
93.9%
Q3 Nov 2025
Operating Margin
-535.5%
Q3 Nov 2025
Net Margin
-649.5%
Q3 Nov 2025
Free Cash Flow (TTM)
−$17.21M
Q3 Nov 2025
Cash
$6.8M
Q3 Nov 2025
Total Debt
$1.38M
Q3 Nov 2025
Shares Outstanding
5.23M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings